Therefore, our study focused on HER2 + /N + breast cancer patients with the goal of pCR and DFS times to evaluate PR status as a predictor of response to neoadjuvant trastuzumab plus pertuzumab treatment in HER2 + /N + breast cancer. Here, ERBB2 is linked to breast carcinoma.